Wockhardt (WOCKPHARMA) Share Price Falls 2.25% Today; Price Action, Valuation and Peer View
- September 1, 2026
- Posted by: Harsh Piplani
- Category: News
Wockhardt Share Price fell to Rs 2,170 on 11 September 2026, down 2.25% for the day, taking the company’s market capitalisation to Rs 36,585.92 crore. The stock declined Rs 49.9 from the previous close of Rs 2,219.9, making it a notable stock-specific move in today’s healthcare market update.
Today’s decline matters because it came after the stock opened at Rs 2,197.05, touched a day high of Rs 2,235.9 and then slipped to a day low of Rs 2,167.25. The supplied data confirms the price event, but it does not establish a company-specific catalyst behind the fall. That keeps the focus on Wockhardt Stock News, price action, valuation and where the stock stands against pharmaceutical peers.
For investors tracking Wockhardt Share Price Today, the key points are clear: the stock remains a Large Cap name, turnover stood at Rs 10.11 crore, valuation multiples are elevated versus the same-industry benchmark, and profitability metrics such as ROE and ROCE remain below industry medians. On Univest, that combination explains why Wockhardt Share News is attracting attention even without a confirmed corporate trigger.
Wockhardt (WOCKPHARMA) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,170 |
| Previous Close | Rs 2,219.9 |
| Today's Move | -Rs 49.90 (-2.25%) |
| Open | Rs 2,197.05 |
| High | Rs 2,235.9 |
| Low | Rs 2,167.25 |
| Turnover | Rs 10.11 crore |
| Market Capitalisation | Rs 36,585.92 crore |
| Market Cap Category | Large Cap |
Wockhardt Share Price Today reflects a clear intraday decline, with the stock moving from an open of Rs 2,197.05 to Rs 2,170 by early afternoon after swinging between Rs 2,235.9 and Rs 2,167.25. The move shows that the day’s early strength did not hold, and the stock drifted close to its intraday low.
Against the previous close of Rs 2,219.9, the stock was lower by Rs 49.9, or 2.25%, at the time of this Wockhardt Share Price Update. Turnover was Rs 10.11 crore, indicating active market participation around the move, while the company’s Large Cap status and market cap of Rs 36,585.92 crore kept it firmly on the radar in Stock Market Today screens.
The day’s range of Rs 68.65 between the high and low also shows meaningful intraday volatility. Even after today’s decline, the stock is still trading above its 50-day moving average of Rs 1,944.96 and its 200-day moving average of Rs 1,664.38, while the RSI reading of 64.27 points to strong momentum rather than weak momentum. That makes valuation and financial quality the next important layer in Wockhardt Stock Analysis.
Wockhardt (WOCKPHARMA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 36,585.92 crore |
| P/E Ratio | 88.19x |
| P/B Ratio | 7.17x |
| ROE | 4.29% |
| ROCE | 6.79% |
| EPS | Rs 25.17 |
| Book Value Per Share | Rs 309.81 |
| Dividend Yield | 0% |
Wockhardt Fundamental Analysis shows a business that commands a sizeable market value but is also trading at demanding multiples relative to its current profitability. At a market capitalisation of Rs 36,585.92 crore, Wockhardt is meaningfully larger than the same-industry median market cap of Rs 750.93 crore and above the industry average of Rs 14,206.91 crore across 200 companies.
On valuation, the stock trades at a P/E ratio of 88.19 and a P/B ratio of 7.17. Those are both above the same-industry median levels of 32.73 and 3.06, and also above the industry averages of 49.1 and 4.42. That means the market is valuing Wockhardt at a premium multiple versus a broad set of pharmaceutical companies.
Profitability, however, is more modest. ROE stands at 4.29 and ROCE at 6.79, both below the industry medians of 11.83 and 13.68 and the averages of 11.22 and 13.71. EPS is Rs 25.17, which represents earnings attributable to each share, while book value per share is Rs 309.81, showing the accounting net worth behind each share. Dividend yield is 0, so the current investment case is not supported by a cash payout. For Univest readers, that mix suggests the stock’s valuation remains an important part of the Wockhardt Latest News discussion.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 88.19x |
| Benchmark Median P/E | 32.73x |
| Benchmark Average P/E | 49.1x |
| Benchmark P/E Range | 3.4x to 701.57x |
| Company P/B Ratio | 7.17x |
| Benchmark Median P/B | 3.06x |
| Benchmark Average P/B | 4.42x |
| Company ROE | 4.29% |
| Benchmark Median ROE | 11.83% |
| Benchmark Average ROE | 11.22% |
| Company ROCE | 6.79% |
| Benchmark Median ROCE | 13.68% |
| Benchmark Average ROCE | 13.71% |
| Company Market Capitalisation | Rs 36,585.92 crore |
| Benchmark Median Market Cap | Rs 750.93 crore |
| Benchmark Average Market Cap | Rs 14,206.91 crore |
Wockhardt operates in Healthcare within the Pharmaceuticals & Drugs industry, and the supplied sector benchmark gives useful context for today’s Wockhardt Share Price Fall. Across 200 same-industry companies, valuation and profitability vary widely, which matters when comparing a premium-rated stock with relatively lower returns.
Within this benchmark, Wockhardt’s P/E of 88.19 is far above the median of 32.73 and above the average of 49.1. It still sits well below the benchmark maximum of 701.57, while the minimum is 3.4 based on 169 companies with P/E data. The company’s P/B of 7.17 is also above the median of 3.06 and average of 4.42 across 199 companies, though below the maximum of 27.2 and above the minimum of -11.38.
Profitability tells a softer story. Wockhardt’s ROE of 4.29 is below both the same-industry median of 11.83 and average of 11.22, while its ROCE of 6.79 is below the median of 13.68 and average of 13.71 across 199 companies. On size, however, Wockhardt’s market cap is above the industry median of Rs 750.93 crore and above the average of Rs 14,206.91 crore, though well below the benchmark maximum of Rs 4,48,315.74 crore. In short, the Healthcare sector comparison shows a large pharmaceutical company trading at above-benchmark valuation levels despite below-benchmark return ratios.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,48,315.74 | 36.98 | 5.17 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,51,737.22 | 85.36 | 14.14 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,87,593.62 | 85.95 | 20.89 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,12,618.18 | 24.71 | 4.14 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,10,515.04 | 33.08 | 3.17 | 11.83 | 16 |
Peer data shows that Wockhardt sits in a different position from several leading pharmaceutical names on both valuation and profitability. Compared with Sun Pharmaceutical Industries, Wockhardt’s market cap of Rs 36,585.92 crore is much smaller than Rs 4,48,315.74 crore, while its P/E of 88.19 is far higher than Sun Pharma’s 36.98. Sun Pharma also reports stronger ROE of 14.85 and ROCE of 19.11.
Against Divi’s Laboratories and Torrent Pharmaceuticals, Wockhardt’s P/E is slightly higher than 85.36 and 85.95 respectively, but its ROE of 4.29 and ROCE of 6.79 are materially lower than Divi’s 16.19 and 21.51, and Torrent’s 26.76 and 19.27. Versus Zydus Lifesciences and Cipla, the contrast is sharper on valuation, with Wockhardt trading at a much higher P/E than 24.71 and 33.08, while still lagging their profitability ratios.
That peer comparison suggests Wockhardt Share Price is being valued closer to premium pharma names on earnings multiples, but without matching their return profile. For Univest users, that is one of the central points to track alongside any fresh Wockhardt Company News or earnings updates.
Why Investors Are Watching Wockhardt
- The stock fell 2.25% to Rs 2,170, down Rs 49.9 from the previous close of Rs 2,219.9.
- Intraday price action stayed weak after an open at Rs 2,197.05, with a high of Rs 2,235.9 and low of Rs 2,167.25.
- The stock remains above its 50-day moving average of Rs 1,944.96 and 200-day moving average of Rs 1,664.38, while RSI is 64.27.
- Valuation is elevated at 88.19 times earnings and 7.17 times book value, while ROE and ROCE are 4.29 and 6.79.
- Same-industry peer and benchmark data show Wockhardt trading above sector median valuation levels despite lower return ratios.
About Wockhardt
Wockhardt is classified in the Healthcare sector and Pharmaceuticals & Drugs industry. Based on the supplied market data, it is a Large Cap pharmaceutical company with a market capitalisation of Rs 36,585.92 crore, placing it above the average same-industry market cap of Rs 14,206.91 crore.
Within the listed pharma universe, the company sits alongside major peers such as Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. That context matters for Wockhardt Stock Performance because investors often assess pharmaceutical stocks through a mix of valuation multiples, return ratios and relative market size. Univest tracks these comparisons to place daily price action in context.
Track Wockhardt Share Price on Univest
UseWockhardt (WOCKPHARMA) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
Investors following Wockhardt Share Price can use Univest to track live share price moves, market capitalisation, valuation ratios, shareholding pattern updates when available, moving averages, RSI, 52-week levels and broader market insights. For readers scanning Wockhardt Stock News and Wockhardt Share Price Live trends, Univest helps connect daily price action with fundamentals, peer metrics and sector benchmarks in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Wockhardt Share Price falling today?
Ans. Wockhardt Share Price was down 2.25% at Rs 2,170, a fall of Rs 49.9 from the previous close of Rs 2,219.9. The supplied data confirms the decline, but it does not identify a company-specific trigger.
What is Wockhardt Share Price Today?
Ans. Wockhardt Share Price Today stood at Rs 2,170 at the time of the update. The stock opened at Rs 2,197.05, touched Rs 2,235.9 on the upside and fell as low as Rs 2,167.25 during the session.
Is Wockhardt a large-cap stock?
Ans. Yes, Wockhardt is classified as a Large Cap company in the supplied market data. Its market capitalisation was Rs 36,585.92 crore, which is also above the same-industry average market cap of Rs 14,206.91 crore.
How expensive is Wockhardt compared with its industry?
Ans. Wockhardt trades at a P/E of 88.19 and a P/B of 7.17. Those are above the same-industry median levels of 32.73 and 3.06, and also above the averages of 49.1 and 4.42.
What do Wockhardt ’s profitability ratios show?
Ans. The company’s ROE is 4.29 and ROCE is 6.79. Both are below the same-industry medians of 11.83 and 13.68, indicating that current return ratios are weaker than broader pharmaceutical industry benchmarks.
What is the EPS and book value of Wockhardt ?
Ans. Wockhardt’s EPS is Rs 25.17, which represents earnings attributable to each share. Its book value is Rs 309.81 per share, showing the accounting net worth backing each share at the current point.
Does Wockhardt pay a dividend?
Ans. The supplied data shows Wockhardt’s dividend yield at 0. That means the current stock metrics do not reflect an active dividend yield contribution, so investor focus remains on price action and valuation instead.
How does Wockhardt compare with major pharma peers?
Ans. Wockhardt’s P/E of 88.19 is above Sun Pharma’s 36.98, Zydus Lifesciences’ 24.71 and Cipla’s 33.08. Its ROE of 4.29 and ROCE of 6.79 are also lower than all five listed comparison peers supplied.
What does today’s price range say about the stock?
Ans. The stock moved between Rs 2,235.9 and Rs 2,167.25 today, a range of Rs 68.65. That suggests meaningful intraday volatility, with the closing-period trade near the lower end of the day’s range.
What should investors monitor next in Wockhardt Stock News?
Ans. Investors may track whether Wockhardt sustains levels above its 50-day moving average of Rs 1,944.96 and 200-day moving average of Rs 1,664.38, while also watching valuation, peer comparisons and any fresh company disclosures.
